Atea Pharmaceuticals, Inc.

This early-stage study is testing a single dose of the drug combination bemnifosbuvir/ruzasvir in 28 adults. Some participants have severe kidney or liver impairment, while others are healthy. The goal is to see how the body processes the drug and whether it is safe in these grou…

This early-stage study looks at how a new antiviral drug combination (BEM/RZR) affects the levels of two common opioid addiction treatments—buprenorphine/naloxone and methadone—in healthy adults. Researchers will give participants their usual opioid therapy plus the antiviral dru…